Compare Ryanair Holdings plc (RYAAY) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ryanair Holdings plc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Ryanair Holdings plc trades at $51.1 (market cap $26.41B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Ryanair Holdings plc is far larger — about 3.5× Spyre Therapeutics Inc. Common Stock's market cap, and Ryanair Holdings plc pays a 1.69% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ryanair Holdings plc for 72 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| RYAAY | SYRE | |
|---|---|---|
Market Cap | $26.41B | $7.52B |
Volume | 2,266,391 | 1,441,031 |
Sector | Industrials | Health |
52-Week High | $73.82 | $108.92 |
52-Week Low | $51.33 | $22.18 |
Typical Hold Time | 72 Days | 0 Days |
Enterprise Value | $23.47B | $6.52B |
Dividend Yield | 1.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RYAAY trades at $51.33, down 3.15% amid bearish technical signals despite strong fundamentals. The stock shows robust profitability with 12.13% net margins and attractive valuation at 13.23 P/E. Recent earnings performance has been mixed with Q1 2026 beating expectations but Q2 2026 missing. Technical indicators signal bearish momentum with oversold RSI conditions, while analyst consensus remains positive with 64.71% buy ratings.
The outlook balances strong operational performance against near-term headwinds including fuel cost volatility and Boeing MAX 10 certification delays. Revenue growth trajectory and market share gains support long-term potential, though elevated oil prices and competitive pressures present significant risks. Current valuation levels offer entry opportunity for patient investors despite technical weakness.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
